Back to search results

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Abroad (travel likely)RecruitingPHASE3

Conditions

Systemic Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Local Institution - 0035, Scottsdale, Arizona, United States

  • University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

    Contact: Study coordinator (Melissa Griffith) · 720-848-7700

  • Local Institution - 0001, Denver, Colorado, United States

  • Local Institution - 0069, Miami, Florida, United States

  • Emory University School of Medicine, Atlanta, Georgia, United States

    Contact: Study coordinator (Arezou Khosroshahi) · 404-778-6638

  • Local Institution - 0139, Chicago, Illinois, United States

  • Local Institution - 0084, Worcester, Massachusetts, United States

  • Local Institution - 0034, Ann Arbor, Michigan, United States

  • Local Institution - 0037, Rochester, Minnesota, United States

  • Local Institution - 0082, Summit, New Jersey, United States

  • Local Institution - 0122, Cleveland, Ohio, United States

  • Local Institution - 0142, Philadelphia, Pennsylvania, United States

  • Local Institution - 0143, Pittsburgh, Pennsylvania, United States

  • Local Institution - 0002, Charleston, South Carolina, United States

  • Local Institution - 0074, Dallas, Texas, United States

  • Local Institution - 0144, Houston, Texas, United States

  • Local Institution - 0008, Seattle, Washington, United States

  • Local Institution - 0057, Leuven, Vlaams-Brabant, Belgium

  • Local Institution - 0080, Liège, Belgium

  • Local Institution - 0104, Halifax, Nova Scotia, Canada

  • Local Institution - 0088, Sherbrooke, Quebec, Canada

  • Local Institution - 0031, Strasbourg, Alsace, France

  • Local Institution - 0061, Toulouse, Haute-Garonne, France

  • Local Institution - 0049, Bordeaux, France

  • Local Institution - 0012, Bron, France

  • Local Institution - 0052, Paris, France

  • Local Institution - 0141, Rennes, France

  • Local Institution - 0046, Berlin, Germany

  • Local Institution - 0016, Cologne, Germany

  • Local Institution - 0028, Erlangen, Germany

  • Local Institution - 0042, Leipzig, Germany

  • Local Institution - 0032, München, Germany

  • Local Institution - 0033, Tübingen, Germany

  • Local Institution - 0038, Würzburg, Germany

  • Local Institution - 0103, Rome, Lazio, Italy

  • Local Institution - 0004, Milan, Milano, Italy

  • Local Institution - 0108, Pisa, Tuscany, Italy

  • Local Institution - 0106, Milan, Italy

  • Local Institution - 0026, Sapporo, Hokkaido, Japan

  • Local Institution - 0132, Yokohama, Kanagawa, Japan

  • Local Institution - 0137, Suita, Osaka, Japan

  • Local Institution - 0117, Bunkyo-ku, Tokyo, Japan

  • Local Institution - 0123, Fukuoka, Japan

  • Local Institution - 0136, Maebashi, Japan

  • Local Institution - 0118, Okayama, Japan

  • Local Institution - 0129, A Coruña, A Coruña [La Coruña], Spain

  • Local Institution - 0138, Barcelona, Catalunya [Cataluña], Spain

  • Local Institution - 0060, Barcelona, Spain

  • Local Institution - 0009, Málaga, Spain

  • Local Institution - 0047, Basel, Switzerland

  • Local Institution - 0068, Bern, Switzerland

  • Local Institution - 0078, Zurich, Switzerland

  • Local Institution - 0140, London, London, City of, United Kingdom

  • Local Institution - 0063, Leeds, West Yorkshire, United Kingdom

  • Local Institution - 0091, Sheffield, Yorkshire and the Humber, United Kingdom

  • Local Institution - 0059, London, United Kingdom

Study leads

  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb

View source on ClinicalTrials.gov(opens in a new tab)